AAIC 2020 transitions to a virtual event — free of charge: For the latest information, policies and how to reach us, visit our COVID-19 updates page.
LOS ANGELES, JULY 14, 2019 — The Alzheimer’s Association has named Dagmar Dolby and David Dolby of the Dolby Family Fund recipients of the 2019 Jerome H. Stone Philanthropy Award for Alzheimer’s Research. The Awards were presented during the plenary session on Monday, July 15 at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles.
Dagmar Dolby and David Dolby are recognized for their philanthropic contributions toward the advancement of Alzheimer’s research, which they make to honor the memory and legacy of sound pioneer Ray Dolby, who passed away with the disease in 2013.
Dagmar is president and David is chief financial officer of the Ray and Dagmar Dolby Family Fund, which helped to found the Dolby Family Center for Mood Disorders at the University of California San Francisco. As philanthropists, the Dolby family has advanced dementia science through their support of the Alzheimer’s Association International Research Grant Program and its Part the Cloud competitions, as well as other academic and nonprofit institutions. They have been a member of the Alzheimer’s Association Zenith Society since 2012.
“Dagmar Dolby and David Dolby are committed, passionate individuals who are leaders in philanthropy and the fight to end Alzheimer’s disease,” said Harry Johns, president and CEO of the Alzheimer’s Association. “The Alzheimer’s Association is deeply grateful for their commitment to accelerating research to identify causes, prevention strategies and ultimately a cure for this terrible disease.”
David is also founder and managing director of Dolby Family Ventures, which supports basic research to explain the root causes of Alzheimer’s disease, biomarkers and diagnostics, cognitive assessment, brain imaging, drug discovery and drug development, clinical trials recruitment and data analysis, as well as direct investments in disease-modifying therapeutics. Dolby Family Ventures’ investment in more than 25 life science companies has advanced the development of 14 novel pharmaceuticals for Alzheimer’s disease.
Established in 2013, the Stone Award is named in honor of Jerome Stone, primary founder of the Alzheimer’s Association. Stone was one of the first private citizens to advocate for investment in Alzheimer’s research. The award underscores the commitment of the Alzheimer’s Association to accelerating the global effort to eliminate Alzheimer’s disease and to recognizing the efforts of researchers who advance understanding of it. Previous Stone Award recipients include: The Alzheimer’s Association Zenith Society (2013), Selim Zilkha and Mary Hayley (2014), GHR Foundation and MetLife Foundation (2015), Jerre and Mary Joy Stead (2016), Michaela “Mikey” Hoag (2017) and Charles F. and Joanne Knight and FBRI (2018).
The Alzheimer’s Association is committed to accelerating the global effort to eliminate Alzheimer’s disease and to recognizing the efforts of philanthropists who further our understanding about this devastating disease. As the worldwide nonprofit leader in funding Alzheimer’s research, we continue to directly fund cutting-edge research with approximately $165 million accelerating advances in more than 450 best-of-field active projects in 25 countries around the world.
About the Alzheimer's Association International Conference® (AAIC®)
The Alzheimer’s Association International Conference (AAIC) is the world’s largest gathering of researchers from around the world focused on Alzheimer’s and other dementias. As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
AAIC 2019 home page: www.alz.org/aaic
AAIC 2019 newsroom: www.alz.org/aaic/pressroom.asp
About the Alzheimer's Association®
The Alzheimer’s Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. Visit alz.org or call +1 800.272.3900.